utilities

Archive | In the news

Football and dementia

Dr Laura PhippsKirsty MaraisClaire LucasRobin BrisbourneCatherine McKeeverKaty Stubbs

Today’s headlines are highlighting a possible link between playing football and a form of dementia related to head injuries. The story is based on a very small study that points to the need for more research into a question that other sports are already having to grapple with. Boxing In 1928 the term ‘punch-drunk’ was […]

Behind the big dementia headlines of 2016: are we getting closer to a cure?

Dr Laura PhippsKirsty MaraisClaire LucasRobin BrisbourneCatherine McKeeverKaty Stubbs

As we embark on a new year of dementia research, let’s take a look back to see how 2016 got us talking about dementia. In Alzheimer’s diseases, there are two hallmark proteins that build up in the brain – amyloid and tau. Unsurprisingly, these two proteins have become the focus of drug discovery research in […]

UK’s biggest dementia research endeavour starts to take shape

Hilary Evans

Today we’re proud to share with you the news that world-renowned Belgian scientist Prof Bart De Strooper will take the helm of the UK Dementia Research Institute (DRI), a multi-centre national Institute being created to transform the landscape of dementia research in this country. It’s been several months since we announced our commitment of £50m […]

Read more

One important myth to overturn another

Hilary Evans

Around 18 months ago, Alzheimer’s Research UK launched its first-ever awareness advertising campaign, with an arresting and urgent film designed to shake society by the lapels in how it thinks about dementia. This is a condition that is hamstrung by decades of sweeping under the carpet; seldom talked-about and frequently misunderstood. In recent years, we […]

Read more

In the news: Aducanumab – new Alzheimer’s trial results announced

Dr Laura PhippsKirsty MaraisClaire LucasRobin BrisbourneCatherine McKeeverKaty Stubbs

With 850,000 people currently living with dementia in the UK, and this number set to rise to over one million by 2025, urgency is building around dementia research and the hunt for new treatments that could benefit the millions of people around the world living with the condition. Many potential drugs for Alzheimer’s target amyloid […]

Behind the headlines: what’s the real story for LMTX?

Dr Laura PhippsKirsty MaraisClaire LucasRobin BrisbourneCatherine McKeeverKaty Stubbs

The UK public woke up this morning to a series of headlines about phase III trial results of a potential Alzheimer’s drug called LMTX (also known as LMTM). The Times (£) placed their report on the front page, while the story was also reported by the Daily Mail, the Daily Express, BBC Online and more. […]

Tagged with:

Silver lining for first anti-tau Alzheimer’s treatment in phase III?

Dr Laura PhippsKirsty MaraisClaire LucasRobin BrisbourneCatherine McKeeverKaty Stubbs

Findings were reported today from the first phase III anti-tau drug in people with mild-to-moderate Alzheimer’s. The drug, called LMTM, was being tested in a 15-month double-blind, controlled trial in 891 people. Sadly, the drug failed to meet the aims it set out to, but there may be a silver lining for the small number who […]

Tagged with:

EU membership and dementia research

Kirsty MaraisClare van LyndenSusan MitchellEmily CookHelen Davies

In 1950, six nations made a deal to tie their countries together politically and economically to try to prevent another war breaking out in Europe. The UK joined them in 1973, during the first wave of new country admissions, to what had become the European Union. Today, the EU is made up of 28 countries […]